Comparison Between Efficacy of Clarithomycin Versus Ceftriaxone in the Treatment of Community Acquired Pneumonia in Children
Keywords:
Efficacy, Clarithromycin, Ceftriaxone, Community Acquired PneumoniaAbstract
Background: The most prevalent infectious scenario which results in hospitals stay as well as death, particularly among the elderly, is community-acquired pneumonia (CAP). It is one of the most common illnesses worldwide with the greatest death rate among pediatric younger than five years old.  Objective: The main goal of the study was to explore the efficacy of clarithromycin versus ceftriaxone in the treatment of community-acquired pneumonia in children. Methodology: From August 2019 to March 2021, a quasi-experimental study was carried out in the pediatric ward at the Department of Pediatrics, Saidu Teaching Hospital Swat, Khyber Pakhtunkhwa, Pakistan. A total of 140 children participated in this study which were divided into two groups treated with ceftriaxone and clarithromycin. Clinical cure, or illness resolution following forty-eight hours of treatment with antibiotics, afebrile status without antipyretic use, respiratory rate <25/min, and/or O saturation >96%, were used to assess the study medications' 2efficacy. Results: Analysis of the efficacy in terms of reduction of fever, respiratory rate, and Oxygen saturation revealed that ceftriaxone was successful in 84% of individuals whereas clarithromycin was effective in 90% of them. Conclusion: For the treatment of community-acquired pneumonia in children both drugs have effects but as compared to ceftriaxone the results of clarithromycin were much better.References
Mandell LA. Community-acquired pneumonia: epidemiology and treatment. Chest 2000; 108:35S–42.
Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86(5):408–16
Margolis P, Gadomski A. The rational clinical examination: does this infant have pneumonia? JAMA 2000; 279(4):308–13
Swedberg E, Shah R, Sadruddin S, Soeripto J. Saving young children from forgotten killer: pneumonia. Am J Physiol Lung Cell Mol Physiol. 2020;319(5):L861–2
Lodha R, Kabra SK, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev. 2013;(6):CD004847.
Barlow G, Nathwani D, Davey P. The effect of implementing the British Thoracic Society community-acquired pneumonia guidelines on antibiotic prescribing and costs in a UK teaching hospital. Clin Microbiol Infect. 2006; 12(5):498–500.
Mardian Y, Menur Naysilla A, Lokida D, Farida H, Aman AT, Karyana M, et al. Approach to identifying causative pathogens of community acquired pneumonia in children using culture, molecular, and serology tests. Front Pediatr. 2021;28:9.
Izadi M, Dadsetan B, Najafi Z, Jafari S, Mazaheri E, Dadras O, et al. Levofloxacin versus ceftriaxone and azithromycin combination in the treatment of community acquired pneumonia in hospitalized patients. Recent Pat Antiinfect Drug Discov. 2018;13(3): 228–39.
Al Saeedy D, Gillani SW, Al-Salloum J, Moosvi A, Eissa M, Gulam SM. Comparative efficacy of beta-lactams and macrolides in the treatment of pediatric pneumonia: a systematic review. Curr Pediatr Rev. 2020;16(4):307–13.
Ashraf H, Chisti MJ, Alam NH. Treatment of childhood pneumonia in developing countries. Health management: Intech Open; 2010
Lee PI, Wu MH, Huang LM, Chen JM, Lee CY. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia. J Microbiol Immunol Infect. 2008;41(1):54-61
English ML, Fredericks CE, Milanesio NA, Rohowsky N, Xu ZQ, Jenta TR, et al. Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. Antimicrob Agents Chemother. 2012;56(4):2037-47
Messinger AI, Kupfer O, Hurst A, Parker S. Management of Pediatric Community-acquired Bacterial Pneumonia. Ped Rev. 2017;38(9):394-409.
Zuberi F, Khan J. Prospective comparison of prediction rules of mortality risk for CAP in a developing country. Int J Tuberc Lung Dis. 2008;12(4):447-52
Charles PG, Whitby M, Fuller AJ, Stirling R, Wright AA, Korman TM, et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis. 2008;46(10):1513-21
Lim WS, Baudouin S, George R, Hill A, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1-55
File Jr TM, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl_3):iii19-32
English ML, Fredericks CE, Milanesio NA, Rohowsky N, Xu Z-Q, Jenta TR, et al. Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational studies. Antimicrob Agen Chem. 2012; 56(4):2037-47.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Pakistan Journal of Chest Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
